Results per Page:
Intermittent hormone therapy for prostate cancer inferior to continuous therapy
Cathy Tangen contributes to international study, finding on again-off again prostate cancer treatment has quality of life benefits, but continuous therapy improves overall survival
Lower income cancer patients less likely to join clinical trials
Joseph Unger-led study finds poor patients stymied by financial, logistical concerns, blocking representation and access to latest therapies